Skip to main content
Zhengye Biotechnology Holding Limited (ZYBT)
Zhengye Biotechnology Holding will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$4.00 - $5.00
Shares Offered
1,250,000
Deal Size
$5.63M

ZYBT Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Year
 20222021
Revenue
260.27214.07
Revenue Growth (YoY)
21.58%-
Cost of Revenue
106.7588.67
Gross Profit
153.52125.39
Selling, General & Admin
63.5658.19
Research & Development
13.4211.37
Other Operating Expenses
10.73.45
Operating Expenses
87.6973.01
Operating Income
65.8352.38
Interest Expense / Income
2.730.93
Other Expense / Income
-0.81-1.62
Pretax Income
54.9145.56
Income Tax
8.176.6
Net Income
55.7446.47
Net Income Common
46.7438.96
Net Income Growth
19.96%-
Free Cash Flow
-9.995.41
Gross Margin
58.98%58.58%
Operating Margin
25.29%24.47%
Profit Margin
17.96%18.20%
Free Cash Flow Margin
-3.84%2.53%
Effective Tax Rate
14.88%14.48%
EBITDA
85.4470.01
EBITDA Margin
32.83%32.71%
Depreciation & Amortization
18.816.01
EBIT
66.6454
EBIT Margin
25.60%25.23%
Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).